Unleashing the full potential of data to accelerate breakthroughs in cancer immunotherapy for patients

Jonathan Chainey, Global Head, Data Standards & Governance, PD Biometrics, Roche

LHC eSOURCE Symposium, 25 August 2020
1. imCORE – Introduction
2. imCORE Funded Studies - Locations & Types
3. imCORE Sites & Data Capabilities - Survey Results
4. imCORE Data Repository & Data Flows
5. The Bigger Picture
6. Next Steps
imCORE* – Introduction

- A **global network** of 27 leading cancer immunotherapy research sites
- Funded by Roche, co-led with Sage Bionetworks
- Goals:
  - Advance and accelerate cancer immunotherapy R&D
  - Harmonize clinical and biomarker data to support data sharing
- Currently 50+ investigator-initiated research studies

*Immunotherapy Centers of Research Excellence*
imCORE Funded Studies - Locations & Types

67% Ex-US
33% US

33% Clinical
28% Preclinical
7% Data mining
32% Translation
What data model (if any) are you using or planning to use to collect clinical data? (select all that apply)

- NA: 5.0%
- CDISC-like: 5.0%
- iMedidata: 5.0%
- Macro: 5.0%
- mCODE: 5.0%
- CDISC: 5.0%
- CRF: 15.0%

Results from 23 (out of 27) responses
Is your site able to provide (send) your study data via FHIR services?

23 responses

- 52.2% Yes
- 21.7% No
- 13% Maybe
- 2% Don't know
- 2% this is a preclinical study only
- 2% Clinical outcomes data not currently in scope
imCORE Data Repository & Data Flows

CDISC selected as data model for imCORE data repository
The Bigger Picture

Healthcare

Academic Research

Clinical Research

Snomed CT
ICD
HL7
mCODE
CDISC

It’s Time to Align!
Next steps

- Build imCORE data repository using data model from Roche (CDISC + extensions)

- Partner with imCORE research sites to increase data capabilities esp. related to CDISC, HL7 FHIR

- Continue to seek alignment between CDISC, HL7
  - Vulcan - HL7 FHIR Accelerator
  - FDA Common Data Model Harmonization (using BRIDG)